Síndrome coronario en pacientes con comorbilidades

  1. García Sebastián, C. 1
  2. Abellas Sequeiros, M. 1
  3. Monteagudo Ruiz, J.M. 1
  4. Zamorano Gómez, J.L. 1
  1. 1 Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades cardiovasculares (IV)

Serie: 13

Número: 38

Páginas: 2190-2198

Tipo: Artículo

DOI: 10.1016/J.MED.2021.07.004 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

El envejecimiento poblacional ha llevado a un aumento de la prevalencia y la complejidad de la enfermedad cardiovascular. La presencia de una alta carga de comorbilidades es frecuente entre estos pacientes, y es un factor pronóstico importante. La evaluación de la comorbilidad se ha convertido en una preocupación, por lo que se han desarrollado índices para evaluar la comorbilidad, como el índice de comorbilidad de Charlson. Algunas de las principales comorbilidades que afectan al pronóstico de estos pacientes son: fragilidad, diabetes mellitus, enfermedad renal crónica, enfermedad pulmonar obstructiva crónica y patología inflamatoria. El peor pronóstico en estos pacientes parece estar relacionado con retrasos diagnósticos ocasionados por su clínica atípica, alteraciones analíticas y electrocardiográficas basales y una menor utilización de terapias con eficacia probada.

Referencias bibliográficas

  • McManus DD, Nguyen HL, Saczynski JS, Tisminetzky M, Bourell P, Goldberg RJ. Multiple cardiovascular comorbidities and acute myocardial infarction: temporal trends (1990–2007) and impact on death rates at 30 days and 1 year. Clin Epidemiol. 2012;4:115-23.
  • Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83.
  • Rashid M, Kwok CS, Gale CP, Doherty P, Olier I, Sperrin M. Impact of co-morbid burden on mortality in patients with coronary heart disease, heart failure, and cerebrovascular accident: a systematic review and meta analysis. Eur Heart J Qual Care Clin Outcomes. 2017;3(1):20-36.
  • Zhang F, Bharadwaj A, Mohamed MO, Ensor J, Peat G, Mamas MA. Impact of Charlson Co-Morbidity Index Score on Management and Outcomes After Acute Coronary Syndrome. Am J Cardiol. 2020;130: 15-23.
  • Sanchis J, Soler M, Núñez J, Ruiz V, Bonanad C, Formiga F. Comorbidity assessment for mortality risk stratification in elderly patients with acute coronary syndrome. Eur J Intern Med. 2019;62:48-53.
  • Walker DM, Gale CP, Lip G, Martin Sanchez FJ, McIntyre HF, Mueller C. Editor’s Choice - Frailty and the management of patients with acute cardiovascular disease: A position paper from the Acute Cardiovascular Care Association. Eur Heart J Acute Cardiovasc Care. 2018;7(2):176-93.
  • Díez Villanueva P, Arizá Solé A, Vidán MT, Bonanad C, Formiga F, Sanchis J. Recomendaciones de la Sección de Cardiología Geriátrica de la Sociedad Española de Cardiología para la valoración de la fragilidad en el anciano con cardiopatía. Rev Esp Cardiol. 2019;72(1):63-71.
  • Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J. Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-56.
  • Abellan van Kan G, Rolland YM, Morley JE, Vellas B. Frailty: toward a clinical definition. J Am Med Dir Assoc. 2008;9(2):71-2.
  • Mitnitski AB, Graham JE, Mogilner AJ, Rockwood K. Frailty, fitness and late-life mortality in relation to chronological and biological age. BMC Geriatr. 2002;2:1.
  • Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489-95.
  • Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL. ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020, 1-79.
  • McGuire DK, Emanuelsson H, Granger CB, Magnus Ohman E, Moliterno DJ, White HD. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J. 2000;21(21):1750-8.
  • Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323.
  • Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM. Comparison of the effects of glucagon like peptide receptor agonists and sodium glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022-31.
  • Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet. 2018;391:939-48.
  • Szummer K, Lundman P, Jacobson SH, Schön S, Lindbäck J, Stenestrand U. SWEDEHEART. Relation between renal function, presentation, use of therapies and in hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med. 2010;268(1):40-9.
  • Goedemans L, Bax JJ, Delgado V. COPD and acute myocardial infarction. Eur Respir Rev. 2020;29(156):190139.
  • Rothnie KJ, Quint JK. Chronic obstructive pulmonary disease and acute myocardial infarction: effects on presentation, management, and outcomes. Eur Heart J Qual Care Clin Outcomes. 2016;2(2):81-90.
  • Cho SG, Jabin Z, Bom HH. Safer stress tests for myocardial perfusion imaging. J Nucl Cardiol. 2019;26(2):629-32.
  • Picano E, Mathias W, Pingitore A, Bigi R, Previtali M. Safety and tolerability of dobutamin atropine stress echocardiography: A prospective, multicenter study. Lancet. 1994;344:1190-4.
  • Golzar Y, Doukky R. Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge. Int J Chron Obstruct Pulmon Dis. 2014;9:129-37.
  • Au DH, Curtis JR, Every NR, McDonell MB, Fihn SD. Association between inhaled beta agonists and the risk of unstable angina and myocardial infarction. Chest. 2002;121(3):846-51.
  • Rottenkolber M, Rottenkolber D, Fischer R, Ibáñez L, Fortuny J, Ballarin E. Inhaled beta-2 agonists/muscarinic antagonists and acute myocardial infarction in COPD patients. Respir Med. 2014;108(8):1075-90.
  • Loke YK, Kwok CS, Singh S. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. Eur Respir J. 2010;35(5):1003-21.
  • Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ. COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-98.
  • White WB, Cooke GE, Kowey PR, Calverley PMA, Bredenbröker D, Goehring UM. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest. 2013;144(3):758-65.
  • Andell P, Erlinge D, Smith JG, Sundström J, Lindahl B, James S. Blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study. J Am Heart Assoc. 2015;4(4):e001611.
  • Crea F, Liuzzo G. Pathogenesis of acute coronary syndromes. J Am Coll Cardiol. 2013;61(1):1-11.
  • Crea F, Liuzzo G. Antiinflammatory treatment of acute coronary syndro-mes: the need for precision medicine. Eur Heart J. 2016;37(30):2414-6.
  • Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H. Inflammation and long term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strate-gy in 1042 consecutive patients. Circulation. 2002;105(12):1412-5.
  • Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ. LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. N Engl J Med.2020;383(19):1838-47.
  • Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballan-tyne C. CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-31.
  • Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP. Efficacy and safety of low dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497-505.
  • Ando T, Adegbala O, Akintoye E, Ashraf S, Briasoulis A, Takagi H. Acute myocardial infarction outcomes in systemic lupus erythematosus (from the Nationwide Inpatient Sample). Am J Cardiol. 2019;123(2):227-32.
  • Fasano S, Margiotta DP, Navarini L, Pierro L, Pantano I, Riccardi A. Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. Lupus. 2017;26(14): 1463-72.
  • Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal antiinflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480-9.
  • Holmqvist M, Ljung L, Askling J. Acute coronary syndrome in new onset rheumatoid arthritis: a population based nationwide cohort study of time trends in risks and excess risks. Ann Rheum Dis. 2017;76(10):1642-7.
  • Vlad CE, Foia L, Popescu R, Ivanov I, Luca MC, Delianu C, Toma V, Statescu C, Rezus C, Florea L. Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease. J Diabetes Res. 2019 Dec 14;2019: 6906278.
  • Ibáñez B, James S, Agewall S, Antunes MJ, Bucciarelli Ducci C, Bueno H. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119-77
Fuente de los datos: Dialnet